Merus (MRUS) Earns News Sentiment Rating of -0.02

Headlines about Merus (NASDAQ:MRUS) have trended somewhat negative this week, according to Accern. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Merus earned a media sentiment score of -0.02 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 47.1936579773566 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media headlines that may have impacted Accern’s scoring:

Several equities analysts have recently issued reports on the company. Zacks Investment Research lowered Merus from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $28.00 target price on shares of Merus in a report on Wednesday, October 18th. ValuEngine lowered Merus from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. BidaskClub raised Merus from a “strong sell” rating to a “sell” rating in a report on Saturday, December 30th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $32.00 target price on shares of Merus in a report on Friday, January 12th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $30.25.

Merus (NASDAQ:MRUS) opened at $18.73 on Thursday. Merus has a twelve month low of $13.23 and a twelve month high of $33.63. The firm has a market capitalization of $352.73, a price-to-earnings ratio of -3.42 and a beta of -0.23.

Merus (NASDAQ:MRUS) last announced its quarterly earnings data on Thursday, November 30th. The biotechnology company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.26). Merus had a negative net margin of 809.20% and a negative return on equity of 119.36%. equities analysts anticipate that Merus will post -4.02 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was posted by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at

Merus Company Profile

Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products inlcude, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as wellas MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

Insider Buying and Selling by Quarter for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit